Search

Your search keyword '"Xie, Peihan"' showing total 40 results
Start Over Author "Xie, Peihan"
40 results on '"Xie, Peihan"'

9. Harnessing Bimetallic Imwa Nanosensitizer to Unleash Ferroptosis and Calcium Overload: Unlocking Tumor Vulnerability for Potentiated Imwa Therapy Against Hepatocellular Carcinoma

Author

Qiu, Guanhua, primary, Wang, Duo, additional, Xie, Peihan, additional, Li, Zelun, additional, Zhou, Niqiang, additional, Zhang, Xiaoqian, additional, Wang, Xiao-bo, additional, Tang, Jiali, additional, Cao, Jun, additional, Liu, Junjie, additional, and Su, Danke, additional

Published
2024
Full Text
View/download PDF

12. Interplay of heart rate variability and resting heart rate on mortality in type 2 diabetes

Author

Huang, Yiquan, primary, Xie, Peihan, additional, Zhang, Shaozhao, additional, Liu, Menghui, additional, Xiong, Zhenyu, additional, Huang, Rihua, additional, Huang, Zhuoshan, additional, Zhong, Xiangbin, additional, Chen, Zhuohui, additional, Zhou, Ziwei, additional, Zhang, Wenjing, additional, Guo, Yue, additional, Yang, Daya, additional, Zhuang, Xiaodong, additional, and Liao, Xinxue, additional

Published
2023
Full Text
View/download PDF

14. Serum Klotho Modifies the Associations of 25-Hydroxy Vitamin D With All-Cause and Cardiovascular Mortality.

Author

Chen, Zhuohui, Liu, Menghui, Xu, Xingfeng, He, Lixiang, Wang, Peng, Cai, Xiaojie, Huang, Rihua, Zhang, Shaozhao, Xu, Xinghao, Lai, Yuhui, Huang, Yiquan, Li, Miaohong, Lin, Yifen, Xie, Peihan, Liao, Xinxue, Zhuang, Xiaodong, and Guo, Yue

Subjects
CARDIOVASCULAR disease related mortality, VITAMIN D metabolism, BLOOD serum analysis
Abstract

Background The association between 25-hydroxyvitamin D and mortality remains controversial. Klotho, a biomarker of vitamin D activation and metabolism, may play a key role in this association. However, it is unclear whether the association between vitamin D deficiency and mortality risk is modified by klotho levels. Therefore, this study investigated the joint association of serum 25-hydroxyvitamin D [25(OH)D] and klotho with mortality risk in American community-dwelling adults. Methods A total of 9870 adults from the National Health and Nutrition Examination Survey (2007-2016) were included in our study. Mortality data were ascertained by linking participants to National Death Index records. Cox proportional hazards models were used to assess the association among serum 25(OH)D, serum klotho, and all-cause and cardiovascular disease (CVD) mortality. Results We found a significant interaction between klotho and serum 25(OH)D in all-cause mortality (P =.028). With klotho > 848.4 pg/mL (risk threshold on mortality), no significant all-cause and CVD mortality risk was observed at any level of serum 25(OH)D. However, with klotho < 848.4 pg/mL, a significant all-cause and CVD mortality risk was observed with serum 25(OH)D < 50 nmol/L [hazards ratio (HR), 1.36; 95% confidence interval (CI), 1.10-1.69; HR, 1.78; 95% CI, 1.16-3.45) and serum 25(OH)D of continuous variable (HR, 0.98; 95% CI,.97-.99; HR, 0.98; 95% CI,.98-.99). In addition, vitamin D metabolism disruption accessed by the combination of decreasing serum 25(OH)D (<50 nmol/L) and klotho (<848.4 pg/mL) was associated with significant all-cause mortality (HR, 1.48; 95% CI, 1.11-1.96) and CVD mortality (HR, 2.36; 95% CI, 1.48-3.75). Conclusions Vitamin D-associated mortality risk is observed only with concurrently decreasing klotho, indicating that vitamin D metabolism dysfunction increases the risk of mortality. Klotho levels could help predict long-term mortality outcomes and thus may be useful concurrently for guiding vitamin D supplementation therapy decision-making in populations with vitamin D deficiency. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Serum klotho modifies the associations of 25-hydroxy vitamin D with all-cause and cardiovascular mortality

Author

Chen, Zhuohui, primary, Liu, Menghui, additional, Xu, Xingfeng, additional, He, Lixiang, additional, Wang, Peng, additional, Cai, Xiaojie, additional, Huang, Rihua, additional, Zhang, Shaozhao, additional, Xu, Xinghao, additional, Lai, Yuhui, additional, Huang, Yiquan, additional, Li, Miaohong, additional, Lin, Yifen, additional, Xie, Peihan, additional, Liao, Xinxue, additional, Zhuang, Xiaodong, additional, and Guo, Yue, additional

Published
2023
Full Text
View/download PDF

17. Body Weight Time in Target Range and Cardiovascular Outcomes in Adults with Overweight/Obesity and Type 2 Diabetes

Author

Liu, Menghui, primary, Xu, Xingfeng, additional, Chen, Xiaohong, additional, Guo, Yue, additional, Zhang, Shaozhao, additional, Lin, Yifen, additional, Zhou, Huimin, additional, Li, Miaohong, additional, Xie, Peihan, additional, Xia, Wenhao, additional, Wang, Lichun, additional, Zhuang, Xiaodong, additional, and Liao, Xinxue, additional

Published
2023
Full Text
View/download PDF

24. Supplemental Material - Impaired left ventricular systolic synchrony in patients with lupus Nephritis: A speckle tracking echocardiography study

Author

He, Wei, Xie, Peihan, Li, Wei, Yao, Fengjuan, Liu, Yanqiu, Liang, Liuqin, and Liu, Donghong

Subjects
111702 Aged Health Care, FOS: Health sciences, skin and connective tissue diseases
Abstract

Supplemental Material for Impaired left ventricular systolic synchrony in patients with lupus Nephritis: A speckle tracking echocardiography study by Wei He, Peihan Xie, Wei Li, Fengjuan Yao, Yanqiu Liu, Liuqin Liang, and Donghong Liu in Lupus

Published
2022
Full Text
View/download PDF

33. Antiplatelet strategy in primary and secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: A perspective from the guideline appraisal

Author

Liu, Menghui, primary, Zhuang, Xiaodong, additional, Chen, Xiaohong, additional, Zhang, Shaozhao, additional, Yang, Daya, additional, Zhong, Xiangbin, additional, Xiong, Zhenyu, additional, Lin, Yifen, additional, Zhou, Huimin, additional, Fan, Yongqiang, additional, Xie, Peihan, additional, Huang, Yiquan, additional, Wang, Lichun, additional, and Liao, Xinxue, additional

Published
2020
Full Text
View/download PDF

35. Antiplatelet strategy in primary and secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: A perspective from the guideline appraisal.

Author

Liu, Menghui, Zhuang, Xiaodong, Chen, Xiaohong, Zhang, Shaozhao, Yang, Daya, Zhong, Xiangbin, Xiong, Zhenyu, Lin, Yifen, Zhou, Huimin, Fan, Yongqiang, Xie, Peihan, Huang, Yiquan, Wang, Lichun, and Liao, Xinxue

Subjects
TYPE 2 diabetes, CORONARY artery bypass, GUIDELINES, CARDIOVASCULAR diseases, PREVENTIVE medicine, SECONDARY prevention
Abstract

Aims/Introduction: To appraise guidelines on the antiplatelet strategy of prevention of cardiovascular disease (CVD) in patients with type 2 diabetes mellitus, and highlight the consensuses and controversies to aid clinician decision‐making. Materials and Methods: A systematic search was carried out for guidelines regarding CVD prevention or focusing on type 2 diabetes patients. Appraisal of Guidelines for Research and Evaluation II instrument was utilized to appraise the quality of included guidelines. Results: Of the 15 guidelines with discrepant Appraisal of Guidelines for Research and Evaluation II scores (66%; interquartile range 51–71%), 10 were defined as "strongly recommended" guidelines. For secondary prevention, >60% of guidelines advocated that the dual antiplatelet therapy was used within 12 months when the type 2 diabetes patients experienced acute coronary syndrome and/or post‐percutaneous coronary intervention or coronary artery bypass grafting, with subsequent long‐term aspirin use. For primary prevention, 80% of guidelines supported that aspirin should not be routinely used by patients with type 2 diabetes. No consensus on whether to prolong dual antiplatelet therapy in secondary prevention, and whether to use aspirin in type 2 diabetes patients with high CVD risk exists in current guidelines. Conclusions: Physicians should use the recommendations from "strongly recommended" guidelines to make informed decisions and know the consensuses of current guidelines. Dual antiplatelet therapy should be used within 12 months when type 2 diabetes patients experience acute coronary syndrome and/or percutaneous coronary intervention/coronary artery bypass grafting, with subsequent long‐term aspirin use. In primary prevention, aspirin should not be routinely used by individuals with type 2 diabetes, but might be considered for those with high CVD risk. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

38. Intensive Glycemic Therapy in Type 2 Diabetes Patients With Cardiac Autonomic Dysfunction

Author

Huang, Yiquan, Xie, Peihan, Zhang, Shaozhao, Liu, Menghui, Huang, Rihua, Xiong, Zhenyu, Zhong, Xiangbin, Lin, Yifen, Zhou, Ziwei, Zhang, Wenjing, Guo, Yue, Yang, Daya, Zhuang, Xiaodong, and Liao, Xinxue

Abstract

To assess whether the presence of cardiac autonomic dysfunction denoted by low heart rate variability (HRV) modifies the effect of intensive glycemic therapy on outcomes in patients with type 2 diabetes.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results